Abstract
Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 131-138 |
| Number of pages | 8 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 1 2013 |
| Externally published | Yes |
Fingerprint
Keywords
- Acute myeloid leukemia
- chronic
- Decitabine
- Myelodysplastic syndromes
- Myelomonocytic leukemia
- Risk factors
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. / Jabbour, Elias; Garcia-Manero, Guillermo; Ravandi, Farhad; Faderl, Stefan; O'Brien, Susan; Fullmer, Amber; Cortes, Jorge E.; Wierda, William; Kantarjian, Hagop.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 2, 01.04.2013, p. 131-138.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine
AU - Jabbour, Elias
AU - Garcia-Manero, Guillermo
AU - Ravandi, Farhad
AU - Faderl, Stefan
AU - O'Brien, Susan
AU - Fullmer, Amber
AU - Cortes, Jorge E.
AU - Wierda, William
AU - Kantarjian, Hagop
PY - 2013/4/1
Y1 - 2013/4/1
N2 - Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.
AB - Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.
KW - Acute myeloid leukemia
KW - chronic
KW - Decitabine
KW - Myelodysplastic syndromes
KW - Myelomonocytic leukemia
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=84877314620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877314620&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2012.11.001
DO - 10.1016/j.clml.2012.11.001
M3 - Article
C2 - 23260600
AN - SCOPUS:84877314620
VL - 13
SP - 131
EP - 138
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2650
IS - 2
ER -